| What is RSS feed? | About Us |
 |
 Search Score: 4/10
Source: au.rd.yahoo.com --- 27 days ago
Health professionals will gather in Wellington later this year with the aim of tackling the country's Melanoma rate. ... Source: www.ncbi.nlm.nih.gov --- 1 day ago
Related Articles Chemoinhibitory Effect of Mulberry Anthocyanins on Melanoma Metastasis Involved in the Ras/PI3K Pathway. J Agric Food Chem. 2008 Sep 4; Authors: Huang HP, Shih YW, Chang YC, Hung CN, Wang CJ Anthocyanins richly exist in mulberry plants and have been well characterized to have various bioactive properties. However, the antimetastasis properties of mulberry anthocyanins (MACs) remain unclear. The objectives of this study were to investigate the inhibitory effects of MACs on the metastasis of B16-F1 cells under noncytotoxic concentrations. Further investigation revealed that the antimetastatic effect of MACs was also evident in a C57BL/6 mice model. First, MACs exhibited an inhibitory effect on the migration ability by wound healing assay and Boyden chamber assay. In the cancer cell metastasis process, matrix degrading proteinases are required. B16-F1 cells treated with MACs at various concentrations showed reduced extracellular matrix (ECM) proteinases including matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) by gelatin zymography assay. The results of the Western blotting assay demonstrated that the expression levels of Ras, phosphoinositide 3-kinase (PI3K), phospho-Akt, and nuclear factor kappa B (NF-kappaB) in the MACs-treated B16-F1 cells were reduced. Therefore, it was suggested that MACs could mediate B16-F1 cell metastasis by reduction of MMP-2 and MMP-9 activities involving the suppressi ... Source: www.moreover.com --- 28 days ago
Cancer Management: A Multidisciplinary Approach, 10th Edition (2007). Each year, more than 1 million people are diagnosed with skin cancer. ... Source: www.ncbi.nlm.nih.gov --- 5 days ago
Related Articles Primary osseous Melanoma in the tibia of a dog. J Am Anim Hosp Assoc. 2008 May-Jun;44(3):139-43 Authors: Stefanello D, Romussi S, Signorelli P, Caniatti M, DiGiancamillo M, Roccabianca P, Avallone G An 18-month-old, female Cane Corso dog was presented with a suspected primary tumor of the tibia. Plain radiographs and computed tomography (CT) of the tibia were highly suggestive of a primary bone neoplasm. A diagnosis of malignant Melanoma was made by cytology. Total body survey radiographs, CT scan of the thorax, and abdominal ultrasound excluded the presence of neoplastic lesions other than in the tibia. Limb amputation was performed. Histology and immunohistochemical analysis of the tibial neoplasm confirmed the diagnosis of a Melanoma with secondary metastasis to the popliteal lymph node. The dog was alive and in good physical condition 43 months after surgery. PMID: 18451072 [PubMed - indexed for MEDLINE] ... Source: www.moreover.com --- 27 days ago
Health professionals will gather in Wellington late this year with the aim of tackling the country's Melanoma rate. ... Source: www.medicalnewstoday.com --- 24 days ago
A drug widely used to treat high cholesterol is helping beat cancer. Lovastatin is part of a new cancer treatment that has arrested or eradicated tumors in more than 80% of initial patients. The first person treated with the investigative protocol in 2000 had stage 4 Melanoma; he remains disease-free today. Lovastatin, the first of the statin group of lipid fighters, was introduced in 1980. ... Source: www.spurl.net --- 3 days ago
The awareness of skin cancer increases everyday as more is known about the disease and more exposure is given to preventing the disease on television and radio than ever before. It is thought to be the most common form of cancer in the United States and Australia alone. Whilst this might be [...] ... Source: cbs2chicago.com --- 3 days ago
Patients vary greatly in their response to the new treatment, with some experiencing a full remission and others having little benefit. CBS 2's Allison Smith reports. ... Source: www.wickedlocal.com --- 23 days ago
The second annual Mike Donohoe 5K Run/Walk for Melanoma will be held Sunday, Oct. 19 at the Perley School parking lot in memory of Michael J. Donohoe. The event raises money to benefit the Melanoma Foundation New England and the Michael J. Donohoe Scholarship Fund. There will be a 5K run/walk up North Street, around Brook Meadow and back down North Street to the Perley School. Children age 8 and under can sign up for the kids’ fun run at 11:30 a.m. around the Perley field and receive a medal. There will be cash prizes, free raffles, giveaways and refreshments including homemade pastries, juicy barbecue hotdogs, and even an old-fashioned popcorn machine. Free long-sleeved t-shirts to the first 200 entries. Cost: $15 before Oct. 1; $20 after Oct. 1 and on race day. Pre-race day number pick-up available on Friday, Oct. 17 from 5-7 p.m. and Saturday, Oct. 18 from 10 a.m. to 1 p.m. at Georgetown Middle/High School. Race day parking available at Georgetown Middle/High School. Those willing to donate this year can submit them to “The Melanoma Foundation New England” and may be mailed to Michael J. Donohoe Road Race/Scholarship Fund, PO Box 878, Georgetown, MA 01833. For more information or to register go to www.liveandrun.com/races/mikedonohoeroadrace or contact Race Directors Deb Johnson and Rich Laflamme at 978-500-9023 or e-mail mikedonohoe5Kroadrace@comcast.net . ... Source: www.tv3.co.nz --- 27 days ago
Young people are the focus of the latest warning about Melanoma rates. ... Source: qnc.queensu.ca --- 15 days ago
Discovering ways to treat and diagnose malignant Melanoma - a deadly and increasingly common type of cancer - has become a passionate focus for pathologist Victor Tron. "Melanoma... ... Source: home.nzcity.co.nz --- 30 days ago
Despite awareness campaign urging people to avoid exposure to sun, Melanoma cases continue to rise ... Source: www.wickedlocal.com --- 24 days ago
The second annual Mike Donohoe 5K Run/Walk for Melanoma will be held Sunday, Oct. 19 at the Perley School parking lot in memory of Michael J. Donohoe. The event raises money to benefit the Melanoma Foundation New England and the Michael J. Donohoe Scholarship Fund. There will be a 5K run/walk up North Street, around Brook Meadow and back down North Street to the Perley School. Children age 8 and under can sign up for the kids’ fun run at 11:30 a.m. around the Perley field and receive a medal. There will be cash prizes, free raffles, giveaways and refreshments including homemade pastries, juicy barbecue hotdogs, and even an old-fashioned popcorn machine. Free long-sleeved t-shirts to the first 200 entries. Cost: $15 before Oct. 1; $20 after Oct. 1 and on race day. Pre-race day number pick-up available on Friday, Oct. 17 from 5-7 p.m. and Saturday, Oct. 18 from 10 a.m. to 1 p.m. at Georgetown Middle/High School. Race day parking available at Georgetown Middle/High School. Those willing to donate this year can submit them to “The Melanoma Foundation New England” and may be mailed to Michael J. Donohoe Road Race/Scholarship Fund, PO Box 878, Georgetown, MA 01833. For more information or to register go to www.liveandrun.com/races/mikedonohoeroadraceor contact Race Directors Deb Johnson and Rich Laflamme at 978-500-9023 or e-mail mikedonohoe5Kroadrace@comcast.net. ... Source: www.emaxhealth.com --- 30 days ago
There is new hope for the treatment of chemotherapy-resistant malignant Melanoma. Novel assay finds that widely prescribed anti-parasite drug targets cancer-causing protein. Researchers at the NYU Cancer Institute and the Ronald O. Perelman Department of Dermatology have identified mebendazole, a drug used globally to treat parasitic infections, as a novel investigational agent for the treatment of chemotherapy-resistant malignant Melanoma. read more ... Source: www.wsls.com --- 25 days ago
At 19 years old Beth Lucas never thought a mole she had removed would come back as cancer. ... Source: www.sciencealert.com.au --- 27 days ago
Thick melanomas, the most dangerous kind of skin cancer, are not getting any rarer in New Zealand, nearly 15 years after early detection strategies were introduced. ... Source: pharmalicensing.com --- 1 day ago
Our client, a Global Pharmaceutical Company, is looking for a Medical Science Manager. Working within the oncology therapy area, your primary role will be to develop and maintain relationships with Key Opinion Leaders as well as providing expert scientific and clinical information to Healthcare Professionals and internal colleagues.Collaborating with colleagues, you will be required to use your scientific and clinical experience and knowledge in order to communicate information related to products within our client'Ts haematology and oncology portfolio. You will spend 70% of your time working in the field visiting Key Opinion Leaders with regular travel to the head office for internal meetings and training.RequirementsWith experience in a scientific and / or clinical research environment, you will have excellent knowledge of the clinical trial processExperience of translating scientific or clinical data into messages to help physicians best serve their patients is key, as well as experience in communicating scientific and / or clinical data to research or healthcare professionalsYou will have good working knowledge of the ABPIIdeally you will live in the Birmingham, Liverpool, Leeds triangle (M6/M62 corridors)You will be either a Medical Doctor or PhD pharmacist with experience in oncology, or a broad medical background, or a scientist with a firm knowledge of oncology and oncology therapeutics.To apply, please contact Tim Wagstaff at R ... Source: keyc.tv --- 4 days ago
In Health Watch tonight:It's the most dangerous form of skin cancer... ... Source: keyetv.com --- 3 days ago
CTLA-4 is an experimental treatment for skin cancer. ...
Find more results for Melanoma on RSSMicro.com |
Copyright © 2008 RSSMicro.com
